- Phase III Trial Design: 990-patient primary cohort with 800 additional patients for F2/F3 NASH, targeting NASH resolution or fibrosis improvement at 52 weeks.
- Clinical Efficacy: 1.8 mg PEMB achieved 7.5% weight loss and antifibrotic effects in 48-week trials, with 43–51% F2/F3 patients projected for treatment.
- Market Potential: 70% of surveyed physicians likely to prescribe PEMB, citing dual mechanism, tolerability, and lean muscle preservation, with 80% viewing it as a first-line option.
- Financial Position: $274M cash at year-end 2025, $27.4M net loss, and $75M capital raise in January to fund Phase III, providing operating runway through 2028.
- Competitive Edge: PEMB’s one-to-one glucagon/GLP-1 ratio differentiates it in NASH, addressing SEMA discontinuation cases and offering reduced titration steps (1–2) for tolerability.
Financial Performance and Valuation
The company's financial results show a cash position of approximately $274 million at year-end 2025, which is expected to provide an operating cash runway into 2028. The company's valuation metrics raise concerns, with a P/E Ratio of -4.04, P/B Ratio of 1.58, and P/S Ratio of 7620.26. The EV/EBITDA ratio is -3.39, indicating that the company's enterprise value is not justified by its earnings. As Jerry Durso stated, "We completed a $75 million capital raise in January to prepare for the planned initiation of our Phase III trial this year."
PEMB's Potential in NASH Treatment
Altimmune's PEMB has shown strong evidence of antifibrotic effect in the IMPACT trials, with substantial improvements in ELF and liver stiffness. The 48-week data also provided evidence of the ability to address metabolic drivers of NASH, with patients receiving 1.8 mg PEMB achieving 7.5% weight loss at 48 weeks. The company's Phase III trial will assess PEMB in patients with moderate to advanced fibrosis, with a primary population of 990 patients.
Market Research and Competitive Landscape
Market research with 75 U.S. healthcare professionals who treat NASH patients identified emerging needs in patient subgroups, including options for NASH patients who have discontinued semaglutide for either tolerability or efficacy reasons. Physicians recognize the promise of PEMB in treating NASH, with over 70% reporting a high likelihood to prescribe it. The company's balanced ratio of GLP-1 to glucagon agonism is believed to be important for tolerability and efficacy.
Conclusion on Valuation Metrics
The company's valuation metrics, such as the P/S Ratio of 7620.26, indicate that investors have high expectations for the company's future revenue growth. However, the net loss and negative EPS raise concerns about the company's ability to meet these expectations. The company's cash position and expected operating cash runway into 2028 provide some comfort, but investors should closely monitor the company's progress in its Phase III trial and its ability to execute on its development plans.